Identification of markers associated with highly aggressive metastatic phenotypes using quantitative comparative proteomics

Cancer Genomics and Proteomics

Volumn 9, Issue 5, 2012, Pages 265-273

  Terp, Mikkel G ^a   Lund, Rikke R ^a   Jensen, Ole N ^a   Leth Larsen, Rikke ^a   Ditzel, Henrik J ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarkers; Cl16 cells; LM3; LRRC59; Metastasis; NM2C5; Proteomics

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CD59 ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; LEUCINE RICH REPEAT CONTAINING 59; PROTEOCHONDROITIN SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER LOCALIZATION; CARCINOGENICITY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGING SYSTEM; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT;

EID: 84867358411     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Lacroix M, Toillon RA and Leclercq G: Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocrine-related cancer 11: 497-522, 2004. (Pubitemid 39331280)
3. Nguyen DX, Bos PD and Massague J: Metastasis: from dissemination to organ-specific colonization. Nature reviews Cancer 9: 274-284, 2009.
4. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D and Goodison S: Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res 8: 61-74, 2002. (Pubitemid 34101460)
5. Goodison S, Kawai K, Hihara J, Jiang P, Yang M, Urquidi V, Hoffman RM and Tarin D: Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 9: 3808-3814, 2003. (Pubitemid 37169252)
6. Goodison S, Viars C and Urquidi V: Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements. Cancer Genetics Cytogenetics 156: 37-48, 2005. (Pubitemid 39601057)
7. Montel V, Huang TY, Mose E, Pestonjamasp K and Tarin D: Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol 166: 1565-1579, 2005. (Pubitemid 40586524)
8. Suzuki M, Mose ES, Montel V and Tarin D: Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 169: 673-681, 2006. (Pubitemid 44156323)
9. Leth-Larsen R, Lund RR and Ditzel HJ: Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 9: 1369-1382, 2010.
10. Ong SE, Foster LJ and Mann M: Mass spectrometric-based approaches in quantitative proteomics. Methods 29: 124-130, 2003. (Pubitemid 36269199)
11. Schwirzke M, Evtimova V, Burtscher H, Jarsch M, Tarin D and Weidle UH: Identification of metastasis-associated genes by transcriptional profiling of a pair of metastatic versus non-metastatic human mammary carcinoma cell lines. Anticancer Res 21: 1771-1776, 2001. (Pubitemid 32728911)
12. Euer N, Schwirzke M, Evtimova V, Burtscher H, Jarsch M, Tarin D and Weidle UH: Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res 22: 733-740, 2002. (Pubitemid 34475222)
13. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC and Urquidi V: The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 65: 6042-6053, 2005. (Pubitemid 40994388)
14. Lund R, Leth-Larsen R, Jensen ON and Ditzel HJ: Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J Proteome Res 8: 3078-3090, 2009.
15. Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON and Ditzel HJ: Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 8: 1436-1449, 2009.
16. Kreunin P, Yoo C, Urquidi V, Lubman DM and Goodison S: Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics 4: 329-339, 2007. (Pubitemid 350067363)
17. Kreunin P, Urquidi V, Lubman DM and Goodison S: Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 4: 2754-2765, 2004. (Pubitemid 39202175)
18. Kreunin P, Yoo C, Urquidi V, Lubman DM and Goodison S: Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 7: 299-312, 2007. (Pubitemid 46184092)
19. Montel V, Mose ES and Tarin D: Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer 119: 251-263, 2006.
20. Lund RR, Terp MG, Laenkholm AV, Jensen ON, Leth-Larsen R and Ditzel HJ: Quantitative proteomics of primary tumors with varying metastatic capabilities using stable isotope-labeled proteins of multiple histogenic origins. Proteomics: 2012. May 23. doi: 10.1002/pmic.201100490. [Epub ahead of print]
21. Rappsilber J, Ishihama Y and Mann M: Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75: 663-670, 2003. (Pubitemid 36176744)
22. Callesen AK, Mohammed S, Bunkenborg J, Kruse TA, Cold S, Mogensen O, Christensen R, Vach W, Jorgensen PE and Jensen ON: Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 19: 1578-1586, 2005. (Pubitemid 40831938)
23. Elias JE, Gibbons FD, King OD, Roth FP and Gygi SP: Intensity-based protein identification by machine learning from a library of tandem mass spectra. Nat Biotechnol 22: 214-219, 2004. (Pubitemid 38160538)
24. Mortensen P, Gouw JW, Olsen JV, Ong SE, Rigbolt KT, Bunkenborg J, Cox J, Foster LJ, Heck AJ, Blagoev B, Andersen JS and Mann M: MSQuant, an open source platform for mass spectrometry-based quantitative proteomics. J Proteome Res 9: 393-403, 2010.
25. Zhen Y, Sorensen V, Skjerpen CS, Haugsten EM, Jin Y, Walchli S, Olsnes S and Wiedlocha A: Nuclear Import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1. Traffic 13: 650-664, 2012.
26. Rodriguez-Enfedaque A, Bouleau S, Laurent M, Courtois Y, Mignotte B, Vayssiere JL and Renaud F: FGF1 nuclear translocation is required for both its neurotrophic activity and its p53-dependent apoptosis protection. Biochim Biophys Acta 1793: 1719-1727, 2009.
27. Bouleau S, Grimal H, Rincheval V, Godefroy N, Mignotte B, Vayssiere JL and Renaud F: FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway. Oncogene 24: 7839-7849, 2005. (Pubitemid 41715190)
28. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ and Waldmann H: CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170: 637-654, 1989. (Pubitemid 19226653)
29. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J and Durrant LG: Loss of CD59 expression in breast tumours correlates with poor survival. J Path 200: 633-639, 2003. (Pubitemid 36987313)
30. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM and Ferrone S: CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 102: 1496-1512, 2010.
31. Rae JM, Creighton CJ, Meck JM, Haddad BR and Johnson MD: MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104: 13-19, 2007. (Pubitemid 46976633)
32. Chambers AF: MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69: 5292-5293, 2009.
33. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB and Yu D: Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64: 3479-3485, 2004. (Pubitemid 38657921)
34. Montel V, Suzuki M, Galloy C, Mose ES and Tarin D: Expression of melanocyte-related genes in human breast cancer and its implications. Differentiation 78: 283-291, 2009.